early asset development
Changing the narrative: why hidden struggles matter
On Suicide Prevention Day, we’re focusing on something often overlooked: the difference between what’s visible and what’s actually being carried. Many people living with long-term or chronic illness experience challenges...
Cutting the friction from health comms through whole-person design
Good design can’t change the reality of illness, remove the pain, or stop the uncertainty. But it can stop learning what comes next from being another burden to carry.
The silent drop-off: How disengagement shows up in everyday behaviour
In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...
Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development
The Alliance calls for funding and expertise for the next phase of its social media project, marking its first direct engagement with oncology, rare disease and cardiology patients
Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions
New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...
Lilly to spend $6.5bn on second of four US manufacturing facilities
The new facility in Texas is expected to create 4,615 manufacturing and construction jobs
Lilly to invest $5bn in US manufacturing facility
The company will create 2,450 high-wage manufacturing and construction jobs
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...